How the Hell do I Prioritize Work, Blog & Find Balance?

Both Sides of the Table

I don’t know Ezra yet but since he’s taking the time to blog (which I hugesly respect) and share thoughts I thought I’d take him up on his challenge and also spill the beans on my secrets. On blogging I blog because I love it. My other secret on blogging?

Entrepreneurshit. The Blog Post on What It’s Really Like.

Both Sides of the Table

It’s 4.50am. Sunday morning. And I couldn’t sleep. I have much on my mind since I just returned from a week on the road. 5 days. 3 cities. Late night Mexican food. Beers. Airports. Delays. I left on a Sunday. I had to miss a full day with my family, camping in the mountains.

Trending Sources

HipGeo Launches Updated iPhone Travel Blogging App

socalTECH

The company said the redesign came after finding that users were interested in using its tools to create blog-like travel and trip journals, rather than the original, animated slideshows the tool provided. networking social blogging travel iphone hipgeo

Blogging for the Hell of It, Not Blogging to Stay Relevant

Both Sides of the Table

I used to love blogging. Blogging proved to be a great way to hone my ideas, have public conversations with people and as it turns out – build meaningful relationships through public dialog that spilled over into the real world. Somewhere along the way blogging changed. Fred Wilson said as much in his blog post today, too. I guess it’s just a reality of blogging and I accept that. I like “single take” blogging.

FDA Landmark Nod: Cancer Drug To Match Tumor Genes, Not Tissue Type

Xconomy

For many years, doctors and researchers have known that cancers in different parts of the body can share genetic abnormalities. For the first time, the FDA has approved a drug based on those abnormalities and not on the organ in which the cancer originated.

Stratim CEO Sees Future with Costly Driverless Cars, but Low Ride Fares

Xconomy

Like many tech entrepreneurs, Sean Behr had a young business that was popular with consumers, but was also losing money. So in February of 2016, he decided to refocus his San Francisco startup on the small, but unexpectedly profitable aspect of his service that could operate in the black.

Expanding Tissue and Squeezing Cells: Meet Xconomy’s Young Innovator Award Finalists

Xconomy

View the Slideshow The finalists in the Young Innovator category of the 2017 Xconomy Awards show that it’s never too early in life to start a company or invent a new technology.

Countering Cybersecurity Turnover: 57 Companies That Do It Best

Xconomy

What does it take to keep highly skilled cybersecurity employees? Salary and benefits are table-stakes.

Woodcock: New Approvals Show FDA is Adapting to Precision Medicine

Xconomy

The randomized controlled trial has long been held up as the gold standard for testing new drugs. But the nation’s top drug evaluator, Janet Woodcock, believes they aren’t necessary for all new experimental treatments.

Amid Gender Gap Talk, Mentor Network Emerges For Women In Health, Bio

Xconomy

It’s been more than a year since an infamous party with hired models in cocktail dresses captured the biotech community’s attention at the 2016 J.P. Morgan conference. There has been plenty of talk since about closing biotech’s notable gender gap. At this year’s J.P

The Winners of the 2017 Xconomy Awards Are…

Xconomy

We are excited to announce the recipients of the first-ever Xconomy Awards.

Ideas 31

Unanimous Advice To FDA: Approve Landmark CAR-T Cancer Therapy

Xconomy

The first ever approval of a new kind of cancer immunotherapy called CAR-T is one step closer.

Xconomy Awards: The Finalists Are….

Xconomy

Boston Boston blog main Boston top stories Boulder/Denver blog main Detroit blog main Indiana blog main National blog main National top stories New York blog main Raleigh-Durham blog main San Diego blog main San Francisco blog main Seattle blog main Texas blog main Wisconsin blog main Life Sciences xconomyawardsboston

Novartis: CAR-T Results In One Month, Or No Charge. Why One Month?

Xconomy

Novartis said Wednesday that it would not charge for its newly approved cellular immunotherapy, tisagenlecleucel (Kymriah)—the first so-called CAR-T product to ever come to market—if it fails to help patients within a month.

Microsoft’s Strategy for Finding What’s Next in Healthcare A.I.

Xconomy

Boston blog main Boulder/Denver blog main Detroit blog main Indiana blog main National blog main National top stories New York blog main Raleigh-Durham blog main San Diego blog main San Francisco blog main Seattle Seattle blog main Seattle top stories Texas blog main Wisconsin blog main Chatbots Data Sharing field programmable gate arrays Field Programmable Gate Arrays (FPGA) Harry Shum healthcare Healthcare A.I.

Novartis Wins Historic FDA Nod, Prices CAR-T For Leukemia at $475,000

Xconomy

Ahead of schedule, Novartis has received the first-ever approval of a genetically modified living cell therapy called CAR-T, which uses a cancer patient’s own immune cells as the medicine.

Should You Bother Targeting the Tech Blogs for Your PR Campaigns?

Both Sides of the Table

6 or 7 years ago when TechCrunch was at its peak market share (they are still strong but many more tech blogs have also popped up) there was a term for getting covered there called “the TechCrunch bounce.” that they probably read the main tech blogs.

Bio Roundup: GOP Vote-a-Rama, Immunotherapy Setbacks, Pharma Revamps

Xconomy

Boston blog main Boulder/Denver blog main Detroit blog main Indiana blog main National National blog main National top stories New York blog main Raleigh-Durham blog main San Diego blog main San Francisco blog main Seattle blog main Texas blog main Wisconsin blog main Accelerator Corp.

Study 30

The Xconomy Roadmap: Top 15 Innovation Areas to Watch (and Disrupt)

Xconomy

View the Slideshow It is a time of great transitions in the technology and business world. Key advances in areas like machine intelligence, agriculture, and healthcare seem poised to transform society—and everyday life.

Bio Roundup: Frazier v. Trump, Data Dumps, New York Steps & More

Xconomy

The CEO of a major U.S. pharmaceutical company was in the news this week, but for a change not because of the cost of drugs. Merck CEO Kenneth Frazier (pictured) was the first of what quickly became a line of CEOs to exit President Trump’s manufacturing council, leading to its dissolution altogether.

VC Confidence Holds Steady in Quarterly Survey, But Reasons Change

Xconomy

Stand up to “Bully” Trump: Bio CEOs Levin, Holtzman Call to Their Peers

Xconomy

Biotech CEOs Jeremy Levin and Steve Holtzman have watched the violence in Charlottesville, VA , and its continuing aftermath with disgust. But they aren’t just upset about the rally, the violence and death, and President Trump’s equivocating blame of “many sides.” Levin, of Ovid Therapeutics (NASDAQ: OVID ), and Holtzman, of Decibel Therapeutics, have been disappointed with their peers.

ASCO Roundup: Checkpoint Combos, Tumor Profiling, Financial Toxicity

Xconomy

[ Note: Ben Fidler coauthored this report.] The American Society of Clinical Oncology conference is wrapping up, and the closely-watched medical meeting-slash-hype machine produced its usual array of data.

15 For ’18: Key Clinical Data to Watch For Next Year (Part 1)

Xconomy

Many of biotech’s biggest stories in 2017 followed the highly anticipated data from clinical studies. There were monumental successes, like the first-ever approval of a genetically modified living cell therapy , the first FDA application for a gene therapy or a medicine using RNA interference. There were also stinging failures, such as the latest in a long line of hyped Alzheimer’s disease drugs to fall flat.

Study 18

Gottlieb Reportedly On Tap to Lead FDA, and Biopharma Exhales

Xconomy

According to several news reports, the Trump administration will nominate Scott Gottlieb to be the new commissioner of the FDA, a selection that had the life sciences industry breathing a sigh of relief Friday afternoon.

News 34

Interesting New Tech Blog for your Radar Screen

Both Sides of the Table

Over the holiday I became aware of a new tech blog that aims to have deep insights into the next generation of technology, which they call The Hypernet.

Power to the Patient: Meet Xconomy’s Patient Partnership Award Finalists

Xconomy

It’s clear at this point that patients are no longer just subjects in clinical trials.

Biotech Roundup: Opioid News, ASH Preview, Boston Bio IPOs & More

Xconomy

The rising death toll from opioids has prompted policymakers to try various ways to take on the problem. President Trump’s opioid commission released its final report this week, calling for expansion of drug courts, better physician training, and penalties for insurers that don’t cover treatment. But the commission did not say how much its recommendations would cost , nor did it offer a way to pay for them. The absence of those details highlight the difficulties in addressing the crisis.

News 23

Blockchain, Banks & the New Web: Q&A With Ethereum Co-founder Lubin

Xconomy

Ethereum co-founder Joe Lubin is calm and soft-spoken when he shares his vision of how blockchain technology and digital currencies could transform the Internet, the global economy, and many aspects of our daily lives. But what he’s talking about could become a raging tempest, and it’s worth paying attention to—especially given the vast sums of money pouring into the sector. Companies have raised more than $1.25

Boston Is Arguably the Heart of Biotech. But Who Makes It So? Have Your Say.

Xconomy

By the end of this year, for the first time, patients with certain deadly types of blood cancer might have a new option, CAR-T cell therapy , to prolong their life. Immunotherapy could further entrench itself as a mainstay of cancer treatment.

Introducing Xconomy Voices (Podcast), Episode 1: Mary Lou Jepsen

Xconomy

It’s always been Xconomy’s mission to reach audiences—both here on our website, and at our many live events around the country—with deep insights into the innovation process, divined from experts embedded in the world’s most important hubs of high-tech entrepreneurship.

Toyota And Others Enabling Self-Driving Cars to Talk to Each Other

Xconomy

Drivers have plenty of ways to communicate with their fellow drivers, beyond the basic turn signal. Some methods are nice, like a friendly wave to beckon a merging car into your lane. Others, not so much. We’ve all probably cursed or honked at another driver, or been given the finger.

With Pitches for HQ2 Made, Cities Wait on Amazon’s 2018 Decision

Xconomy

From Portland to Pittsburgh, it’s likely that every city in the U.S. with more than 1 million people has made its case to Amazon to locate the company’s second headquarters there. At least, hopefully they have already, because today—if you haven’t heard—was the deadline to apply.